Articles

CHAMPION PHOENIX clinical study anti-platelet therapy cangrelor ACC 13

The experimental anti-clotting drug cangrelor solidly outperformed commonly used clopidogrel in a large global trial of patients who underwent coronary stent procedures, according to data from the...

The American Society of Echocardiography (ASE) has released a list of five interventions whose appropriateness physicians and patients should discuss as part of Choosing Wisely, an initiative of...

Rox Medical announced enrollment of the first U.K. patients in the CONTROL-HTN international randomized controlled trial of the Rox Flow procedure for the treatment of resistant hypertension.

This is a roundup of some of the DAIC editor's choice of the most innovative new technologies showcased at ACC 2013, including products in the areas of interventional cardiology, patient...

Thoratec Corp. announced that it has successfully completed the first human use of HeartMate PHP (percutaneous heart pump). The first PHP patient was supported for over 60 minutes during a high-...

 

St. Jude Medical announced publication of results from its landmark RESPECT clinical trial in The New England Journal of Medicine.

 

Minimally invasive procedures significantly lower health payer costs and result in fewer missed workdays when compared to open surgery, according to a study published this week in the ...

Abbot MitraClip

Abbott announced that the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee has voted by majority (Yes: 5, No: 3) that the benefits...

Edwards Sapien, PARTNER, 3 year followup

The three-year results of a pivotal clinical study comparing the Edwards Sapien transcatheter heart valve and open-heart surgery demonstrated comparable outcomes. These new data from The PARTNER...

ekos, pulmonary embolism, clot busting

Results of the ULTIMA trial using endovascular therapy to treat submassive pulmonary embolism (PE) were presented at the American College of Cardiology 2013 meeting, The trial is the first...